Fundz

NeoImmuneTech Welcomes a New President for Its Development and Business

PRIVATEJan 15, 2024

Position

President of Operations

Company

NeoImmuneTech

Luke Oh
loh@neoimmunetech.com
RockvilleBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

NeoImmuneTech announces the appointment of Luke Oh, Ph.D., as President, effective immediately.

Quick answer

NeoImmuneTech Welcomes a New President for Its Development and Business (January 15, 2024). NeoImmuneTech is based in Rockville, Maryland, United States.

What did NeoImmuneTech announce on January 15, 2024?
NeoImmuneTech announces the appointment of Luke Oh, Ph.D., as President, effective immediately.
What does NeoImmuneTech do?
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases.
Where is NeoImmuneTech based?
NeoImmuneTech is based in Rockville, Maryland, United States.
Which similar companies made leadership changes around the same time?
Alkeus Pharmaceuticals (January 23, 2024), Acadia Pharmaceuticals (January 31, 2024), Corvus Pharmaceuticals, Inc. (February 6, 2024) and Disc Medicine (February 7, 2024) also announced leadership changes within 45 days of NeoImmuneTech.

Source: Fundz verified event record.

Other recent leadership changes in Therapeutics and Pharmaceutical

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at NeoImmuneTech, and when

A new leader at NeoImmuneTech brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day NeoImmuneTech raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at NeoImmuneTech, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at NeoImmuneTech. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

NeoImmuneTech

Location

Rockville, Maryland, United States

About

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment NeoImmuneTech changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Luke
Likely contact at this company
••••••••@••••••••

See Luke's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for NeoImmuneTech's next move

Learn about Strategic plan

NeoImmuneTech changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.